Cargando…
Targeted Therapies for Pancreatic Cancer
Pancreatic cancer is the third leading cause of cancer related death and by 2030, it will be second only to lung cancer. We have seen tremendous advances in therapies for lung cancer as well as other solid tumors using a molecular targeted approach but our progress in treating pancreatic cancer has...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5836068/ https://www.ncbi.nlm.nih.gov/pubmed/29382159 http://dx.doi.org/10.3390/cancers10020036 |
_version_ | 1783303906213756928 |
---|---|
author | Amanam, Idoroenyi Chung, Vincent |
author_facet | Amanam, Idoroenyi Chung, Vincent |
author_sort | Amanam, Idoroenyi |
collection | PubMed |
description | Pancreatic cancer is the third leading cause of cancer related death and by 2030, it will be second only to lung cancer. We have seen tremendous advances in therapies for lung cancer as well as other solid tumors using a molecular targeted approach but our progress in treating pancreatic cancer has been incremental with median overall survival remaining less than one year. There is an urgent need for improved therapies with better efficacy and less toxicity. Small molecule inhibitors, monoclonal antibodies and immune modulatory therapies have been used. Here we review the progress that we have made with these targeted therapies. |
format | Online Article Text |
id | pubmed-5836068 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-58360682018-03-07 Targeted Therapies for Pancreatic Cancer Amanam, Idoroenyi Chung, Vincent Cancers (Basel) Review Pancreatic cancer is the third leading cause of cancer related death and by 2030, it will be second only to lung cancer. We have seen tremendous advances in therapies for lung cancer as well as other solid tumors using a molecular targeted approach but our progress in treating pancreatic cancer has been incremental with median overall survival remaining less than one year. There is an urgent need for improved therapies with better efficacy and less toxicity. Small molecule inhibitors, monoclonal antibodies and immune modulatory therapies have been used. Here we review the progress that we have made with these targeted therapies. MDPI 2018-01-29 /pmc/articles/PMC5836068/ /pubmed/29382159 http://dx.doi.org/10.3390/cancers10020036 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Amanam, Idoroenyi Chung, Vincent Targeted Therapies for Pancreatic Cancer |
title | Targeted Therapies for Pancreatic Cancer |
title_full | Targeted Therapies for Pancreatic Cancer |
title_fullStr | Targeted Therapies for Pancreatic Cancer |
title_full_unstemmed | Targeted Therapies for Pancreatic Cancer |
title_short | Targeted Therapies for Pancreatic Cancer |
title_sort | targeted therapies for pancreatic cancer |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5836068/ https://www.ncbi.nlm.nih.gov/pubmed/29382159 http://dx.doi.org/10.3390/cancers10020036 |
work_keys_str_mv | AT amanamidoroenyi targetedtherapiesforpancreaticcancer AT chungvincent targetedtherapiesforpancreaticcancer |